Cardiorentis AG
Records under this name other than patents Cardiorentis AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Cardiorentis AG
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,732,406 | Use of Natriuretic Peptide for Treating Heart Failure Term ended Term ended Nov 17, 2026 · High confidence | Term ended | Term ended Nov 17, 2026 | High confidence |
| US 8,710,006 | Use of natriuretic peptide for treating heart failure Lapsed on the fee record Ended Apr 29, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 29, 2026 | From the USPTO record |
| US 9,023,794 | Use of natriuretic peptide for treating heart failure Term ended Ended no later than Apr 7, 2026 · From the USPTO record | Term ended | Ended no later than Apr 7, 2026 | From the USPTO record |
| US 9,358,271 | Use of natriuretic peptide for treating heart failure Term ended Ended no later than Apr 7, 2026 · From the USPTO record | Term ended | Ended no later than Apr 7, 2026 | From the USPTO record |
| US 8,293,711 | Use of natriuretic peptides for treating angioedema syndromes Lapsed on the fee record Ended Oct 23, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 23, 2020 | From the USPTO record |